Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (1866${count})

  • Alpha-Synuclein Imaging, 2020
    PET Imaging Probe Development for Alpha-synuclein
    Ken Griffin Alpha-synuclein Imaging Competition Logo

    Study Rationale:
    Alpha-synuclein is a protein that can clump to form Lewy bodies and lewy neurites, which are a hallmark of Parkinson's disease. Being able to identify these clumps in living patients...

  • Alpha-Synuclein Imaging, 2020
    Alpha-Synuclein PET Tracer Discovery
    Ken Griffin Alpha-synuclein Imaging Competition Logo

    Study Rationale:
    The discovery of new treatments for Parkinson’s disease has been slowed by the time it takes to answer the question “did a drug work” in a clinical trial. Tests that can assess...

  • Alpha-Synuclein Imaging, 2020
    Optimization of Morphomer-Based Alpha-synuclein PET Tracers
    Ken Griffin Alpha-synuclein Imaging Competition Logo

    Study Rationale:
    The team at AC Immune has discovered a variety of compounds that can bind to a specific Parkinson’s disease-associated form of the protein alpha-synuclein. AC Immune has previously...

  • Therapeutic Pipeline Program, 2020
    Anle138b Clinical Phase 1 Studies: Food Effect, Safety and Tolerability as well as Pharmacokinetics in Parkinson´s Disease Patients

    Study Rationale: 
    Clumps of the protein alpha-synuclein, called Lewy bodies, are a hallmark of Parkinson’s disease and a promising target for therapeutic development. Anle138b is a drug-like compound...

  • Target Advancement Program, 2020
    The Role of Cannabinoid Receptor 2 in Inflammatory Responses Triggered by Alpha-synuclein

    Study Rationale:
    There is growing interest in the anti-inflammatory properties of cannabis-related compounds as a potential therapy for Parkinson’s disease (PD). Cannabis, or marijuana, acts on...

  • Research Grant, 2020
    Targeting TNFR2 in a Model of Parkinson’s Disease

    Study Rationale:
    In previous research, we demonstrated that the protein tumor necrosis factor receptor 2 (TNFR2) plays an essential role in reducing inflammation in the peripheral and central nervous...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.